Valuation as at 2026-08-14 · see also the S&P 500 Most Undervalued screen
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Regeneron Pharmaceuticals, Inc. REGN
Healthcare · Biotechnology
Regeneron Pharmaceuticals, Inc.'s price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per quarter
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 3.0% | 6.1% | 9.1% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 6.66% | 5.66% | 4.66% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.68% + 0.19 × 5.50% = 5.72% · WACC = weighted by 97%/3% capital structure
These numbers come from running Regeneron Pharmaceuticals, Inc.'s cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or REGN's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with REGN →
More S&P 500 stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the S&P 500 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Regeneron Pharmaceuticals, Inc. (REGN) undervalued?
The Base-case DCF estimates intrinsic value at $1,126.36 vs a price of $805.97 on 2026-08-14 — a +39.8% margin, so the Base case reads undervalued. This is a mechanical output, not advice.